This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Luminex's Earnings Take a Deep Dive

Stocks in this article: LMNX

Once these most recent quarterly results are finalized, they will be run through Ratings' model and our ratings will be adjusted accordingly. To keep up to date on all of our ratings, visit Ratings Screener.

On Feb. 5, 2009, Luminex (LMNX) reported that its earnings in Q4 FY08 plunged 81.8% year-over-year due to the absence of gain on settlement of litigation and liability recorded during the prior-year quarter. Earnings totaled $2.01 million or $0.05 per share compared to $11.06 million or $0.30 per share a year ago. Excluding non-recurring items, LMNX swung to earnings of $2.01 million or $0.05 per share from a year-earlier loss of $2.78 million or $0.08 per share. The latest quarterly earnings missed the consensus estimate of $0.06 per share.

Luminex's revenue grew 31.1% to $28.20 million from $21.50 million in the previous year's quarter, reflecting an 18.0% rise in system shipments and a 53.0% and 44.0% increase in consumable and royalty revenue, respectively. Looking at the company's business segments, the Technology Group's revenue rose 26.6% to $22.07 million from $17.43 million. Similarly, revenue from the Assay Group soared 50.4% to $6.13 million from $4.07 million a year ago.

For the quarter ended December 2008, gross profit margin expanded 751 basis points to 69.41% from 61.90% a year ago, as revenue growth outpaced the rise in cost of revenue. During the quarter, Luminex received clearance from the Health Canada for its xTAG Respiratory Viral Panel.

For FY08, the company's revenue grew 39.2% to $104.45 million from $75.01 million in FY07, supported by strong revenue growth in both of its segment. Higher revenue and absence of a year earlier litigation settlement gain helped LMNX to post earnings of $3.06 million or $0.08 per share compared to a loss of $2.71 million or $0.08 per share in the previous year.

Looking forward, Luminex expects revenue in FY09 to be between $130.00 million and $140.00 million, which represent an increase of around 25.0% to 34.0% over FY08.

A detailed report covering this quarterly release is now available. To purchase the report, click here .

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs